UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
SAN DIEGO, Aug. 31, 2016 -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that Scott Wolchko, President and Chief Executive Officer, will be presenting at two upcoming investor conferences in September:
- 2016 Wells Fargo Healthcare Conference at 1:45 p.m. ET on Wednesday, September 7, 2016 in Boston.
- Rodman & Renshaw 18th Annual Global Investment Conference at 11:15 a.m. ET on Tuesday, September 13, 2016 in New York City.
Live webcasts of the presentations will be available through the investor relations section of the Company's website at www.fatetherapeutics.com. Following the live webcasts, archived replays of each presentation will be available on the Company's website for 30 days after the respective conference.
About Fate Therapeutics, Inc.
Fate Therapeutics is a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline is comprised of immuno-oncology programs, including off-the-shelf NK- and T-cell cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for regulating autoimmunity. Its adoptive cell therapy programs are based on the Company’s novel ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.
Contact: Jesse Baumgartner Stern Investor Relations, Inc. 212.362.1200 [email protected]
